Crh director Richard H Fearon buys $570,000 of shares
Open market purchase reported on Form 4, filed Nov 10, 2026.
Snapshot
Richard H Fearon, a director of Crh (CRH), bought 6,000 shares in open market purchases on Nov 6, 2026, about $570,000 at an average price of $94.95 a share, according to a Form 4 filed with the SEC on Nov 10, 2026.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($CRH) | ▼ −2.43% | 93.92 |
as of 16:00 ET · Realtime derived data
What We Know
The filing lists 1 open market purchase line: • Nov 6, 2026: 6,000 shares at $94.95.
After the last purchase, the filing reports 150,842 shares held directly in that account.
Octans View
The purchases raised the holding reported in that account by about 4.1%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.
Bear Case · Room for Disagreement
Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.
Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Form 4 filed by Richard H Fearon for Crh, Nov 10, 2026
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
More on $CRH
4 reports
Black Stone Minerals chair Thomas L Carter Jr buys $686,000 of shares
Open market purchase reported on Form 4, filed Nov 10, 2026.
Electra Therapeutics director Carl L Gordon buys $745,000 of shares
Open market purchase reported on Form 4, filed Nov 10, 2026.
Electra Therapeutics director Orbimed Advisors Llc buys $745,000 of shares
Open market purchase reported on Form 4, filed Nov 10, 2026.
Prothena 10% owner William P Scully buys $1.2 million of shares
Open market purchase reported on Form 4, filed Nov 10, 2026.